Tolerability and Positive Efficacy Results after Subcutaneous Immunotherapy with Parietaria Judaica Depot Extract
- 17 October 2018
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (14) , 1253-1263
Abstract
Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion:P. judaica subcutaneous immunotherapy (Allergovac((R)) depot ROXALL Medicina Espana S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.Keywords
Funding Information
- ROXALL Medicina España S.A., Zamudio
This publication has 34 references indexed in Scilit:
- Open‐label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patientsClinical and Translational Allergy, 2013
- SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trialJournal of Allergy and Clinical Immunology, 2012
- GA2LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthmaAllergy, 2010
- PRS31 A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPEValue in Health, 2008
- Tolerance and immunological changes of chemically modified allergen vaccine ofParietaria judaicain accelerated schedulesClinical and Experimental Immunology, 2007
- Long‐term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trialAllergy, 1999
- Long‐term follow‐up of nasal immunotherapy to Parietaria: clinical and local immunological effectsClinical & Experimental Allergy, 1997
- Immunotherapy with an alum‐adsorbed Parietaria‐pollen allergoid: a 2‐year, double‐blind, placebo‐controlled studyAllergy, 1997
- Immunotherapy with Alpare® in patients with respiratory allergy to Parietaria pollen: a two year double‐blind placebo‐controlled studyClinical & Experimental Allergy, 1995
- Allergy in the Mediterranean area I. Pollen counts and pollinosis of MontpellierClinical & Experimental Allergy, 1984